Spatial Transcriptomics of TNBC tumours and corresponding lymph node metastasis reveals immune hubs driven by TNF/NF-κB signalling of TMSB4X and CD74 expressing cells.

This study utilizes spatial transcriptomics to demonstrate that TNBC lymph node metastases are characterized by expanded TNF/NF-κB-driven immune hubs centered on TMSB4X and CD74-expressing cells, which coordinate myeloid-endothelial crosstalk to promote metastatic persistence.

The Gist

Imagine a Triple-Negative Breast Cancer (TNBC) tumor not just as a lump of bad cells, but as a chaotic city under construction. In this city, the "bad" cancer cells are the builders, but they can't build a new city (a metastasis) on their own. They need a whole support crew: security guards, construction workers, and delivery drivers.

This paper is like a high-tech map that shows us exactly how this city changes when the cancer decides to move from its original home (the breast) to a new location (the lymph nodes).

Here is the story of what they found, broken down into simple terms:

1. The "Command Centers" (The Immune Hubs)

The researchers used a special camera called Spatial Transcriptomics. Think of this as a super-powered drone that doesn't just take a photo of the city; it listens to every conversation happening in every neighborhood.

They discovered that in the original tumor, there are specific "command centers" or hubs. These aren't run by the cancer cells themselves, but by a mix of immune cells and support cells.

• The Key Players: Two specific proteins, TMSB4X and CD74, act like the "mayors" of these hubs.
• What they do: They organize a loud, inflammatory party. They turn on a specific alarm system called NF-κB/TNF signaling. In simple terms, this is a "fight or flight" signal that tells the cells to get ready for war, grow faster, and stick together.

2. The Move: From a Small Town to a Big Metropolis

The most exciting part of the study is comparing the original tumor (Primary Tumor) to the lymph node metastasis (the new city).

• In the Original Tumor: The "alarm system" (NF-κB) is active, but it's contained. It's like a small town square where a few people are shouting. The signal stays local, mostly within those specific immune hubs.
• In the Lymph Node Metastasis: When the cancer moves to the lymph node, the city explodes. The "alarm" isn't just in the square anymore; everyone is shouting. The signal spreads everywhere.
  • The New Twist: The lymph node city adds a new alarm system called IL-1, making the inflammation even louder and more chaotic.
  • The New Boss: In the original tumor, the "construction workers" (Fibroblasts) were the main organizers. But in the lymph node, the blood vessel cells (Endothelial cells) take over as the bosses. They become the central coordinators, telling the immune cells and cancer cells what to do.

3. The "Myeloid-Endothelial" Handshake

The paper highlights a special handshake between two groups:

• Myeloid Cells: Think of these as the "security guards" or "messengers" of the immune system.
• Endothelial Cells: These are the "plumbers" and "road builders" (blood vessels).

In the metastatic lymph nodes, these two groups start talking to each other constantly. The security guards tell the road builders to build more roads (blood vessels) so the cancer can get supplies. The road builders tell the security guards to stay and protect the cancer. This conversation is driven by the TMSB4X and CD74 "mayors."

4. Why Does This Matter? (The Takeaway)

Why should you care about this map?

• It explains why it's hard to treat: TNBC is aggressive because it creates these loud, inflammatory environments that protect it. The cancer isn't just hiding; it's actively recruiting the body's own defense and plumbing systems to help it grow.
• New Targets for Medicine: The researchers found that if we can stop the "mayors" (TMSB4X and CD74) or cut the "handshake" between the security guards and the road builders, we might be able to stop the cancer from setting up shop in the lymph nodes.
• Different Strategies for Different Stages: The study suggests that the cancer behaves differently in the breast than in the lymph nodes. A drug that works on the original tumor might not work on the metastasis because the "bosses" have changed. We need treatments that target these specific "hubs" and the new "vascular bosses" in the lymph nodes.

The Big Picture Metaphor

Imagine the cancer is a weed.

• In the garden (Breast): The weed is growing, and a few specific bugs (immune hubs) are helping it.
• In the forest (Lymph Node): The weed has moved. It hasn't just grown; it has built a fortress. It has convinced the forest's water pipes (blood vessels) and the forest's security dogs (immune cells) to work for the weed. The whole forest is now noisy and chaotic, helping the weed spread.

This paper gives us the blueprint of that fortress, showing us exactly which wires to cut to stop the weed from taking over the forest.

Technical Summary

1. Problem Statement

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options and a high propensity for early metastasis. While axillary lymph node (LN) involvement is a critical prognostic factor, the spatial organization of signaling networks that drive metastatic colonization and persistence in LNs remains poorly understood. Bulk and single-cell RNA sequencing (scRNA-seq) approaches often lose the spatial context necessary to understand cell-cell interactions. There is a knowledge gap regarding whether the signaling networks in primary tumors (PT) are preserved or rewired in LN metastases, and how specific microenvironmental niches facilitate this progression.

2. Methodology

The study employed a multi-omics approach integrating spatial transcriptomics with independent single-cell datasets:

• Cohort & Samples: Four paired TNBC samples consisting of primary tumors (PT) and matched lymph node metastases (LN) were analyzed. All samples were formalin-fixed paraffin-embedded (FFPE).
• Spatial Transcriptomics (ST):
  • Platform: 10x Genomics Visium Spatial Gene Expression (VSGE) for FFPE.
  • Processing: RNA quality was assessed via DV200 (≥60% required). Libraries were sequenced on Illumina NextSeq 550.
  • Analysis Pipeline: Data was processed using Space Ranger, Seurat (v5.3), and Loupe Browser.
  • Deconvolution: Robust Cell Type Decomposition (RCTD) was used with a scRNA-seq reference (GSE180286) to estimate cell-type proportions within spots.
  • Trajectory Analysis: Monocle3 was used to order cells along a pseudotemporal axis to identify developmental drivers.
  • Communication Analysis: CellChat (v2.2.0) was utilized to infer ligand-receptor interactions and pathway-level signaling.
• Validation:
  • Independent Datasets: Results were validated against two public scRNA-seq datasets: GSE180286 (TNBC PT/LN) and GSE176078 (TNBC atlas).
  • Functional Enrichment: KEGG pathway analysis (clusterProfiler) was performed on differentially expressed genes (DEGs).
  • CNV Analysis: inferCNV was used to distinguish malignant epithelial cells from normal cells.

3. Key Contributions

• Identification of TMSB4X-CD74 Hubs: The study identifies TMSB4X (Thymosin Beta-4) and CD74 (MHC Class II Invariant Chain) as conserved trajectory-driving genes that define spatially distinct "immune hubs" in TNBC.
• Spatial Rewiring of Signaling: It demonstrates a fundamental shift in the TNF/NF-κB signaling axis between primary tumors and metastases. While PTs show localized signaling, LN metastases exhibit widespread, multicentric inflammatory networks.
• Cellular Hierarchy Shift: The research reveals a transition in the "organizing" cell type of the tumor microenvironment (TME): from Cancer-Associated Fibroblasts (CAFs) dominating signaling in primary tumors to Endothelial Cells assuming central coordinating roles in lymph node metastases.
• Myeloid-Endothelial Crosstalk: It establishes a conserved, bidirectional communication loop between myeloid and endothelial cells as a core driver of metastatic persistence, mediated by specific ligand-receptor pairs (e.g., CXCL, OSM, VEGF, APP).

4. Key Results

A. Spatial Architecture and Cell Composition

• Malignant cells and CAFs were the dominant compartments in both PT and LN.
• TMSB4X and CD74 expression defined specific clusters that were spatially isolated niches located at the interface of malignant and stromal compartments. These clusters showed high probabilities of immune and stromal cell identities but low malignant probabilities, suggesting they represent transitional or communication-active states.

B. Signaling Pathways and Trajectory Drivers

• Trajectory Analysis: TMSB4X and CD74 emerged as the top two trajectory-driving genes across all samples.
• Pathway Activation: These high-expression clusters were enriched for NF-κB, TNF, PI3K-Akt, and Rap1 signaling.
• PT vs. LN Differences:
  • Primary Tumors: NF-κB/TNF signaling was confined to localized immune hubs.
  • Lymph Node Metastases: Signaling was expanded across all cellular compartments. Crucially, LN metastases showed additional IL-1 pathway activation (a potent NF-κB activator) absent in primary tumors, creating a broader, more pro-survival inflammatory environment.
  • Receptor Shift: Metastases showed increased contribution from TNFRSF1B (associated with survival/immunomodulation) compared to the TNFRSF1A dominance in primary tumors.

C. Cell-Cell Communication Networks

• Primary Tumors: Signaling was driven largely by CAFs via Laminin, APP, and CD99 networks.
• Lymph Node Metastases: Endothelial cells became the major organizers.
  • Endothelial cells signaled to dendritic, myeloid, and B/plasma cells via APP and CD99/SELPLG.
  • Myeloid-Endothelial Crosstalk: Myeloid cells acted as dominant hubs in the TME, signaling to malignant and endothelial cells via Galectin, CXCL, SPP1, FN1, and OSM.
  • Validation: Independent scRNA-seq analysis confirmed that LYVE1⁺ lymphatic endothelial cells and specific myeloid subsets (e.g., LAM1⁺/FABP5⁺, EGR1⁺ macrophages, SIGLEC1⁺ macrophages) are enriched for TMSB4X-CD74 co-expression and drive NF-κB, PI3K-Akt, and EMT pathways.

5. Significance and Clinical Implications

• Mechanistic Insight: The study provides a spatially resolved model of metastatic progression, showing that TNBC metastasis is not just a proliferation of cancer cells but a rewiring of the immune-vascular ecosystem.
• Therapeutic Targets:
  • TMSB4X and CD74 are proposed as biomarkers for inflammatory metastatic niches and potential therapeutic targets.
  • Disrupting the myeloid-endothelial crosstalk (e.g., blocking CXCL/OSM/VEGF axes or ICAM-mediated adhesion) could prevent metastatic persistence.
  • Targeting the CD74-MIF axis shows preclinical promise.
• Strategic Shift: The findings suggest that therapies effective in primary tumors may fail in metastases due to the shift from CAF-driven to endothelial-driven signaling and the amplification of IL-1/NF-κB networks. This underscores the need for stage- and site-specific therapeutic strategies.
• Methodological Value: The study highlights the necessity of integrating spatial transcriptomics (to map niche architecture) with scRNA-seq (to resolve rare cell populations like specific myeloid/endothelial subsets) to fully understand complex tumor ecosystems.

In conclusion, this paper redefines TNBC lymph node metastasis as a state of spatially expanded inflammatory networks centered on TMSB4X-CD74 hubs, driven by coordinated myeloid-endothelial signaling, offering new avenues for biomarker development and targeted therapy.